SQUARE PHARMACEUTICALS IN NEW DRIVE WITH PC PHARMA

Square Pharmaceuticals Ltd., (SPL) the pioneer pharmaceuticals manufacturer  and market leader in the Bangladesh pharmaceuticals industry since 1985 has joined hands with PC Pharma (Pvt) Ltd., to market its branded generics and niche molecules in Sri Lanka.

Square Pharmaceuticals ranked 5th in the world by the WHO scores high in the areas of technological leadership, innovations and commitment to superior quality products. Over 600 Square products currently marketed in more than 20 countries worldwide meet the challenges and opportunities posed by a dynamic global pharmaceutical market on a daily basis.

Square Pharmaceuticals’ state of the art GMP (Good Manufacturing Practices) manufacturing facilities at Dhaka and Pabna comply with the most stringent quality requirements dictated by International Standardizing bodies such as The ISO, EMEA, MHRA – UK and the FDA of USA. These facilities also have the rare distinction of being enlisted for UNICEF global supply.

Technical collaborative arrangements with reputed global player such as Janssen Pharmaceuticals of Belgium and F. Hoffmann-La Roche Ltd., of Switzerland has lead Square Pharmaceuticals to a estimable position in industry related technical skill and manufacturing excellence.
Square Pharmaceuticals also holds the rare honour of being the only pharmaceutical company of Bangladesh origin to receive approval from the Medicine Registration Authority (MHRA) to export their pharmaceuticals locally manufactured to the United Kingdom.  

PC Pharma although a new entrant to the Healthcare market in Sri Lanka has already carved a niche for itself and is gaining the momentum necessary to establish  the company as a key player in the industry. PC Pharma would be initially concentrating on launching the Cardiovascular, Respiratory, Dermatological, Antibiotic product categories and special niche molecules of the Square range and plans to introduce several other innovative products and healthcare concepts from Square in the near future.